Short Interest in FibroGen, Inc. (NASDAQ:FGEN) Expands By 7.2%

FibroGen, Inc. (NASDAQ:FGEN) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 4,320,000 shares, a growth of 7.2% from the October 15th total of 4,030,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the days-to-cover ratio is currently 3.7 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th. StockNews.com assumed coverage on FibroGen in a report on Thursday, November 14th. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On FibroGen

Hedge funds have recently bought and sold shares of the business. Alpine Global Management LLC bought a new position in FibroGen in the 1st quarter valued at $25,000. Delap Wealth Advisory LLC bought a new position in FibroGen in the 1st quarter valued at $27,000. Point72 DIFC Ltd lifted its holdings in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares during the period. Doheny Asset Management CA purchased a new stake in shares of FibroGen in the 2nd quarter worth $48,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of FibroGen in the 1st quarter worth $131,000. Institutional investors own 72.71% of the company’s stock.

FibroGen Stock Performance

Shares of FGEN traded up $0.01 during mid-day trading on Tuesday, hitting $0.35. 673,628 shares of the stock were exchanged, compared to its average volume of 2,216,060. The company has a market cap of $34.92 million, a PE ratio of -0.27 and a beta of 0.72. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93. The firm has a 50-day moving average of $0.36 and a two-hundred day moving average of $0.70.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same period last year, the company earned ($0.52) earnings per share. On average, sell-side analysts predict that FibroGen will post -0.86 EPS for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.